Cholinesterase inhibitors in Alzheimer's disease: Efficacy in a non-selected population

Functional Neurology

Volumn 18, Issue 4, 2003, Pages 233-237

  Sinforiani, Elena ^a   Banchieri, Lara Maria ^a   Zucchella, Chiara ^a   Bernasconi, Luca ^a   Nappi, Giuseppe ^a,b  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acetyl cholinesterase inhibitors; Alzheimer's disease; Follow up

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NEUROLEPTIC AGENT; RIVASTIGMINE;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; COGNITION; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PATIENT SELECTION; PHYSICAL CAPACITY; POPULATION RESEARCH; PREDICTION; PUBLIC HEALTH SERVICE; SEX DIFFERENCE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS;

EID: 1242330886     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Burns A, Rossor M, Hecker J et al. The effects of donepezil in the treatment of Alzheimer's disease - results from a multinational clinical trial. Dement Geriatr Cogn Disord 1999;10:237-244
2. Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318: 633-638
3. O'Brien JT, Ballard CG. Drugs for Alzheimer's disease. BMJ 2001;323:123-124
4. Mohs RC, Doody RS, Morris JC et al.; "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57:481-488
5. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268
6. Cummings JL. Cholinesterase inhibitors: expanding application. Lancet 2000;356:2024-2025
7. Doody RS, Dunn JK, Clark CM et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12:295-300
8. Winblad B, Engedal K, Soininen H et al. A 1-year randomised placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12: 189-198
10. Feldman H, Guathier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week randomised double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:487-492
11. Weiner MF, Martin-Cook K, Foster BM, Saine K, Fonatine CS, Svetlik DA. Effects of donepezil on emotional/behavioural symptoms in Alzheimer's disease patients. J Clin Psychiatry 2000;61:613-620
12. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease. A meta analysis. JAMA 2003;289:210-216
13. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DL, De Kosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neusurg Psychiatry 2002;72:310-311
14. Frisoni GB. Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice. J Neurol 2001;248:551-558
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease; report of the NINCDS-ADRDA Work Group. Neurology 1984;34;939-944
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC; American Psychiatric Association 1994
17. Dementia Study Group of the Italian Neurological Society. Guidelines for the diagnosis of dementia and Alzheimer's disease. The Dementia Study Group of the Italian Neurological Society. Neurol Sci 2000;21:187-194
18. Cornwell Y, Forbes NT, Cox C, Caine ED. Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale. J Am Geriatr Soc 1993;41:38-41
19. Parmalee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;43:130-137
20. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186
21. Lawton MP. Scales to measure competence in every-day activities. Psychopharmacol Bull 1988;24:695-697
22. Govoni S, Lanni C, Racchi M. Advances in understanding the pathogenetic mechanisms of AD. Funct Neurol 2001; 16(4 Suppl):17-30